1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Pharmaceuticals Group
235 East 42nd Street
New York, New York 10017
1-212-573-2222

Pfizer Ltd
Ramsgate Road
Sandwich, Kent
CT13 9NJ
United Kingdom
+00 44 (0)1304 616161

Material Name: Codeine Poly(styrene-divinylbenzene) Sulfonate Syrup

Trade Name: Codipront® Mono Retard
Chemical Family: Mixture
Intended Use: Pharmaceutical product used as cough medicine

2. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citric acid monohydrate</td>
<td>5949-29-1</td>
<td>Not listed</td>
<td>*</td>
</tr>
<tr>
<td>Codeine Poly(styrene-divinylbenzene) Sulfonate</td>
<td>Not Assigned</td>
<td>Not listed</td>
<td>0.2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>CAS Number</th>
<th>EU EINECS List</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydrogel 843T</td>
<td>Not Assigned</td>
<td>Not listed</td>
<td>*</td>
</tr>
<tr>
<td>Sodium saccharin</td>
<td>128-44-9</td>
<td>204-866-1</td>
<td>*</td>
</tr>
<tr>
<td>Sorbitol</td>
<td>6706-59-8</td>
<td>Not listed</td>
<td>*</td>
</tr>
<tr>
<td>Propylparaben</td>
<td>94-13-3</td>
<td>202-307-7</td>
<td>*</td>
</tr>
<tr>
<td>Edetate disodium</td>
<td>139-33-3</td>
<td>205-358-3</td>
<td>*</td>
</tr>
<tr>
<td>Sodium bicarbonate</td>
<td>144-55-8</td>
<td>205-633-8</td>
<td>*</td>
</tr>
<tr>
<td>Flavor</td>
<td>NOT ASSIGNED</td>
<td>Not listed</td>
<td>*</td>
</tr>
<tr>
<td>Methylparaben</td>
<td>99-76-3</td>
<td>202-785-7</td>
<td>*</td>
</tr>
<tr>
<td>Water, purified</td>
<td>7732-18-5</td>
<td>231-791-2</td>
<td>*</td>
</tr>
<tr>
<td>Sodium phosphate, monobasic</td>
<td>7558-80-7</td>
<td>231-449-2</td>
<td>*</td>
</tr>
<tr>
<td>Erythrosine (CI 45430)</td>
<td>16423-68-0</td>
<td>240-474-8</td>
<td>*</td>
</tr>
</tbody>
</table>

Additional Information:
* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

3. HAZARDS IDENTIFICATION

Appearance: Red syrupy liquid

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:
Known Clinical Effects: The most frequently observed adverse reactions to codeine include lightheadedness, dizziness, drowsiness, nausea, vomiting, constipation, and depression of respiration. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Clinical use of this drug has caused addiction, symptoms of dependence/withdrawal.

EU Indication of danger: Not classified

Additional Information: Codeine is classified by the DEA as a Schedule II controlled substance.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

4. FIRST AID MEASURES

Eye Contact: Flush eye(s) immediately with plenty of water. If irritation occurs or persists, get medical attention.

Skin Contact: Wash skin with soap and water. If irritation occurs or persists, get medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Not an expected route of exposure. If discomfort occurs, get medical attention.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Measures for Environmental Protections: Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.
7. HANDLING AND STORAGE

General Handling: Avoid contact with eyes. Wash thoroughly after handling.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Codeine Poly(styrene-divinylbenzene) Sulfonate

Pfizer OEL TWA-8 Hr: 0.07mg/m³
The exposure limit(s) listed for solid components are only relevant if dust may be generated.


Engineering Controls: Engineering controls should be used as the primary means to control exposures.

Personal Protective Equipment:

Hands: Not required for the normal use of this product. Wear protective gloves when working with large quantities.

Eyes: Not required under normal conditions of use. Wear safety glasses or goggles if eye contact is possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with large quantities.

Respiratory protection: Not required for the normal use of this product.

9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State: Syrupy liquid

Molecular Formula: Mixture

Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Stability: Stable under normal conditions of use.

Conditions to Avoid: None known

Incompatible Materials: None known

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Codeine Poly(styrene-divinylbenzene) Sulfonate

Rat Oral LD50 427 mg/kg
Rat Subcutaneous LD50 229 mg/kg
Acute Toxicity Comments:
A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Citric acid monohydrate
Eye Irritation Rabbit Mild
Skin Irritation Rabbit Mild

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Codeine Poly(styrene-divinylbenzene) Sulfonate
14 Day(s) Mouse Oral 3000 mg/kg NOEL None identified
13 Week(s) Rat Oral 450 mg/kg/day NOEL None identified
13 Week(s) Mouse Oral 1000 mg/kg/day NOEL None identified

Sodium saccharin
36 Week(s) Rat Oral 756 g/kg LOAEL Kidney, Ureter, Bladder
54 Day(s) Rat Oral 32400 mg/kg LOAEL Immune system

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Codeine Poly(styrene-divinylbenzene) Sulfonate
Embryo / Fetal Development Mouse Oral 150 mg/kg/day NOEL Maternal toxicity, Embryotoxicity, Not teratogenic
Embryo / Fetal Development Hamster Oral 20 mg/kg/day NOEL Embryotoxicity, Not Teratogenic

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Codeine Poly(styrene-divinylbenzene) Sulfonate
2 Year(s) Rat Oral, in feed 70 NOEL Not carcinogenic
2 Year(s) Mouse Oral, in feed 400 NOEL Not carcinogenic

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

Sodium saccharin
IARC: Group 3
12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be avoided.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and regulations.

14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Not classified

OSHA Label: Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

WHMIS hazard class: None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Sodium saccharin
- Inventory - United States TSCA - Sect. 8(b): Present
- Australia (AICS): Present
- EU EINECS List: 204-886-1

Citric acid monohydrate
- Australia (AICS): Present

Propylparaben
- Inventory - United States TSCA - Sect. 8(b): Present
16. OTHER INFORMATION

Reasons for Revision: Updated Section 3 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal Considerations.

Prepared by: Toxicology and Hazard Communication
Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

End of Safety Data Sheet